NFKB1 and head and neck squamous cell carcinoma: Thus, 3-HBI exhibited both anti-cancer and anti-inflammatory activities and might be a novel effective therapeutic drug for head and neck cancer since NF-κB signalling pathways are targeted for therapeutic applications in many cancers including HNSCC.